Ron Bentsur, Chairman & CEO, 10% Owner at Nuvectis Pharma, Inc. (NVCT), bought 260 shares at $16.19 ($4K) on 2023-07-07, disclosed to the SEC on 2023-07-18.
Open-market purchase of $4k NVCT by Chairman & CEO, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.19 | 110 | $2K | 44.1% |
| 2 | $15.03 | 150 | $2K | 55.9% |
| Total | $15.52 avg | 260 | $4K | 100% |
| Filing → |
| NVCT | BUY | 2024-12-26 | $21K | — | Filing → |
| NVCT | BUY | 2024-11-18 | $98K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |